Evista is a medication that is commonly prescribed to treat and prevent osteoporosis in postmenopausal women. It belongs to a class of drugs known as selective estrogen receptor modulators (SERMs), which work by mimicking the effects of estrogen in the body.
One of the key benefits of Evista is its ability to help increase bone density and reduce the risk of fractures in women with osteoporosis. It does this by slowing down the breakdown of bone tissue and promoting the formation of new bone. This can be especially important for women who are at a higher risk of developing osteoporosis due to factors such as age, family history, or certain medical conditions.
In addition to its effects on bone health, Evista has also been shown to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis. This makes it a valuable treatment option for women who are looking to address multiple health concerns with one medication.
As with any medication, it is important to discuss the potential benefits and risks of Evista with your healthcare provider before starting treatment. They can help determine if this medication is the right choice for you based on your individual health history and risk factors.
Overall, Evista can be a valuable tool in the management of osteoporosis and breast cancer risk in postmenopausal women. By working with your healthcare provider to develop a personalized treatment plan, you can take steps to protect your bone health and overall well-being.
EN 
ES 
FR 
PT 
ZH